Creating a new biomaterial to enhance immunotherapy for liver cancer treatment
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
This study is testing a new treatment called IP-001 that could help boost the immune system's fight against liver cancer after it’s been treated with heat therapy, and it’s aimed at giving hope to patients with this condition by potentially lowering the chances of the cancer coming back.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunophotonics, INC. NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project ID | NIH-10930125 on NIH RePORTER |
What this research studies
This research focuses on developing a synthetic biopolymer called IP-001, which is designed to improve the effectiveness of systemic immunotherapy following microwave thermal ablation for hepatocellular carcinoma (HCC). The approach involves injecting this biomaterial into tumors immediately after they are treated with thermal ablation, which helps to enhance the immune response against cancer cells. The research aims to complete preclinical safety and efficacy testing to support future clinical trials. By targeting local tumors and potentially reducing recurrence rates, this innovative treatment could offer new hope for patients with HCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who are undergoing microwave thermal ablation.
Not a fit: Patients with advanced liver cancer who are not candidates for thermal ablation or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for liver cancer, potentially improving survival rates and reducing recurrence.
How similar studies have performed: While the specific approach of using IP-001 is novel, similar strategies involving immunotherapy and thermal ablation have shown promise in other studies.
Where this research is happening
St. Louis, UNITED STATES
- Immunophotonics, INC. — St. Louis, United States (Active)
Researchers
- Principal investigator: Lam, Siu Kit — Immunophotonics, INC.
- Study coordinator: Lam, Siu Kit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.